Unknown OBSERVATIONAL NCT00388687

Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer

Hypoxia Imaging With the Novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic Impact in Cervical Cancer

Sponsor: Medical University of Vienna

Conditions Uterine Cervical Neoplasms

Interventions 18F Fluoroazomycin Arabinoside (FAZA)

Updated 5 times since 2017 Last updated: Oct 16, 2006 Started: Jul 31, 2006 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Uterine Cervical Neoplasms, this trial is ongoing. The trial is conducted by Medical University of Vienna and has accumulated 5 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Apr 2018 — Jan 2021 [monthly]

Unknown Status

Phase: PHASE2 → None
Jan 2017 — Apr 2018 [monthly]

Unknown Status PHASE2

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University of Vienna

Data source: Medical University of Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria